PCSK9 inhibitor
AssessTechniques
A class of drugs that lowers LDL cholesterol by blocking the PCSK9 protein.
Why it's here
Placed in Assess: 1 article(s) of evidence from 1 source(s), led by regulatory news, with 1 in the last 30 days. Confidence 24%. Low accumulated evidence, so it defaults conservatively pending more signal.
Evidence (1)
- 7Hacker News·7/19/2026regulationFDA Approves First Oral PCSK9 Cholesterol Drug
The U.S. FDA has approved a first-in-class oral PCSK9 inhibitor for adults with high cholesterol, offering a pill-based alternative to injectable treatments. The drug is intended to lower LDL cholesterol in patients who need additional lipid reduction beyond existing therapies.